机构地区:[1]天津中医药大学中医药研究院,中药功效物质重点实验室,天津301617 [2]现代中医药海河实验室,天津301617 [3]组分中药国家重点实验室,天津301617
出 处:《天津中医药》2024年第5期649-658,共10页Tianjin Journal of Traditional Chinese Medicine
基 金:天津市现代中医药海河实验室科技项目(22HHZYJC00003);天津市现代中医药海河实验室科技项目(22HHZYSS00007)。
摘 要:[目的]采用数据挖掘和网络药理学初步探讨大血藤治疗高脂血症的可能作用机制。[方法]借助PubMed和CNKI检索“大血藤化学成分”或“红藤成分”进行资料收集和化合物筛选,用Origin Pro 2021软件对涉及中药的功效类别等进行频数分析,用SPSS Modeler 18.0软件进行关联规则分析和聚类分析。利用Swiss ADME平台来预测候选化合物的吸收度和类药性的相关参数。采用Swiss Target Prediction平台来收集预测到的所有靶点,以“hyperlipidemia”“dyslipidemia”等为关键词检索Genegards、Drug Bank Database等数据库中高脂血症的潜在靶点,通过Uniprot数据库去重和校正靶点名称,取活性成分和高脂血症靶点交集,进而运用Cytoscape 3.8.0软件来进行网络可视化并筛选核心靶点基因。通过DAVID 6.8数据库进行基因本体(GO)功能富集分析和京都基因和基因组百科全书(KEGG)通路富集分析,预测交集靶点作用机制,并绘制气泡图等进行可视化。[结果]通过数据挖掘对大血藤的用药配伍规律进行分析,结果显示性味以温性、寒性和苦味、辛味为主,归经方面以肝、脾为主,配伍以当归、甘草、红花等关联密切,研究结果与中药治疗高脂血症用药规律一致。中药-化合物-靶点网络包含了43个活性成分和相应靶点133个,关键靶点涉及类视黄酸受体α(RXRA)、信号转导及转录激活蛋白3(STAT3)、90 kDa热休克蛋白αA1(HSP90AA1)、蛋白激酶Bα(AKT1)、磷酸肌醇3-激酶调节亚基1(PIK3R1)、雌激素受体1(ESR1)、过氧化物酶体增殖物激活受体(PPAR)A、核受体亚家族3C组成员1(NR3C1)等。GO功能富集分析得到条目437个(P<0.01),KEGG通路富集分析筛选得到57条信号通路(P<0.05)。[结论]大血藤可以通过多个活性成分干预血脂异常中的多个靶点、多个环节,从多维、系统的层面参与调控血脂代谢和高脂血症的发生发展过程,为大血藤的进一步开发利用提供理论�[Objective]To explore the possible mechanism of Sargentodoxa cuneata in the treatment of hyperlipidemia by data mining and network pharmacology.[Methods]PubMed and CNKI were used to search for“chemical constituents of Sargentodoxa cuneata”or“components of Sargentodoxa cuneata”for data collection and compound screening.Origin Pro 2021 software was used to analyze the frequency of efficacy categories involving traditional Chinese medicine.SPSS Modeler 18.0 software was used for association rule analysis and cluster analysis.The Swiss ADME platform was used to predict the absorption and drug-like properties of candidate compounds.Swiss Target Prediction platform was used to collect all the predicted targets.The potential targets of hyperlipidemia in Genegards,Drug Bank Database and other databases were searched with“hyperlipidemia”and“hyperlipidemia”as keywords.The target names were removed and corrected by Uniprot database,and the intersection of active components and hyperlipidemia targets was taken.Cytoscape 3.8.0 software was used to visualize the network and screen the core target genes.GO function enrichment analysis and KEGG pathway enrichment analysis were performed through the DAVID 6.8 database to predict the mechanism of action of the intersection targets,and the mapping was visualized.[Results]Through data mining,the law of drug compatibility of sargentodoxa cuneata was analyzed.The results showed that the nature and flavor were mainly warm,cold,bitter and pungent,and the meridian was mainly liver and spleen.The compatibility was closely related to angelica,licorice and safflower.The results are consistent with the medication rule of traditional Chinese medicine in the treatment of hyperlipidemia.Traditional Chinese medicine-compound-target network contained 43 active components and 133 corresponding targets.The key targets involved RXRA,STAT3,HSP90AA1,AKT1,PIK3R1,ESR1,PPARA,NR3C1,etc.GO functional enrichment analysis obtained 437 items(P<0.01),and KEGG pathway enrichment analysis screene
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...